[{"id":"5c11c440-bc76-462e-910a-049f565460fd","acronym":"KEYNOTE-G02","url":"https://clinicaltrials.gov/study/NCT06682806","created_at":"2025-02-25T16:03:02.738Z","updated_at":"2025-02-25T16:03:02.738Z","phase":"Phase 2","brief_title":"A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation","source_id_and_acronym":"NCT06682806 - KEYNOTE-G02","lead_sponsor":"Prelude Therapeutics","biomarkers":" SMARCA4","pipe":"","alterations":" ","tags":["SMARCA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • PRT3789"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 02/01/2025","start_date":" 02/01/2025","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-03"}]